Compare Stocks: TTNP, QNCX, SGMO, and BRNS

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$0.74	$0.64	$0.51 ▼ $1.83	$30.23M	-0.37	83,130 shs	N/A
QNCX Quince Therapeutics	$29.55 +2.0%	$26.35	$15.10 ▼ $909.98	$30.06M	1.31	18,616 shs	11,341 shs
SGMO Sangamo Therapeutics	$0.07	$0.07	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A
TTNP Titan Pharmaceuticals	$5.93 +23.7%	$5.01	$3.53 ▼ $5.76	$7.88M	1.37	76,658 shs	3.10 million shs

7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	-2.50%	+23.35%	+10.28%	-32.73%
QNCX Quince Therapeutics	0.00%	-5.65%	-8.82%	+58.24%	-90.82%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	-50.99%	-86.08%
TTNP Titan Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+33.15%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BRNS Barinthus Biotherapeutics	$0.74	$0.64	$0.51 ▼ $1.83	$30.23M	-0.37	83,130 shs	N/A
QNCX Quince Therapeutics	$29.55 +2.0%	$26.35	$15.10 ▼ $909.98	$30.06M	1.31	18,616 shs	11,341 shs
SGMO Sangamo Therapeutics	$0.07	$0.07	$0.06 ▼ $0.77	$30.66M	1.3	8.10 million shs	N/A
TTNP Titan Pharmaceuticals	$5.93 +23.7%	$5.01	$3.53 ▼ $5.76	$7.88M	1.37	76,658 shs	3.10 million shs

7 Energy Stocks to Buy and Hold Forever

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BRNS Barinthus Biotherapeutics	0.00%	-2.50%	+23.35%	+10.28%	-32.73%
QNCX Quince Therapeutics	0.00%	-5.65%	-8.82%	+58.24%	-90.82%
SGMO Sangamo Therapeutics	0.00%	0.00%	0.00%	-50.99%	-86.08%
TTNP Titan Pharmaceuticals	0.00%	0.00%	0.00%	0.00%	+33.15%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BRNS Barinthus Biotherapeutics	2.00	Hold	$4.00	440.54% Upside
QNCX Quince Therapeutics	2.42	Hold	$260.00	779.86% Upside
SGMO Sangamo Therapeutics	1.75	Reduce	$5.50	7,332.43% Upside
TTNP Titan Pharmaceuticals	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest TTNP, QNCX, SGMO, and BRNS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/27/2026	QNCX Quince Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/26/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
8/26/2026	BRNS Barinthus Biotherapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Hold
8/25/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/20/2026	QNCX Quince Therapeutics	Craig Hallum Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$68.00
8/18/2026	QNCX Quince Therapeutics	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$70.00
8/12/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/11/2026	BRNS Barinthus Biotherapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/29/2026	QNCX Quince Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
7/29/2026	QNCX Quince Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Outperform	$82.00

(Data available from 9/13/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	$1.82 per share	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	($128.18) per share	N/A
SGMO Sangamo Therapeutics	$39.55M	0.78	N/A	N/A	($0.04) per share	-1.85
TTNP Titan Pharmaceuticals	N/A	N/A	N/A	N/A	$2.67 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BRNS Barinthus Biotherapeutics	-$66.43M	-$1.03	N/A	N/A	N/A	N/A	-59.15%	-43.80%	11/6/2026 (Estimated)
QNCX Quince Therapeutics	-$83.98M	-$156.71	N/A	N/A	N/A	N/A	N/A	-133.84%	11/11/2026 (Estimated)
SGMO Sangamo Therapeutics	-$122.93M	-$0.38	N/A	N/A	N/A	-310.81%	-2,662.06%	-132.12%	N/A
TTNP Titan Pharmaceuticals	-$4.71M	-$2.95	N/A	N/A	N/A	N/A	-108.60%	-95.64%	N/A

Latest TTNP, QNCX, SGMO, and BRNS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/14/2026	Q2 2026	QNCX Quince Therapeutics	-$28.02	-$12.31	+$15.71	-$12.31	N/A	N/A
8/7/2026	Q2 2026	BRNS Barinthus Biotherapeutics	-$0.28	-$0.26	+$0.02	-$0.26	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BRNS Barinthus Biotherapeutics	N/A	N/A	N/A	N/A	N/A
QNCX Quince Therapeutics	N/A	N/A	N/A	N/A	N/A
SGMO Sangamo Therapeutics	N/A	N/A	N/A	N/A	N/A
TTNP Titan Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BRNS Barinthus Biotherapeutics	N/A	5.54	5.54
QNCX Quince Therapeutics	N/A	14.52	14.52
SGMO Sangamo Therapeutics	N/A	0.84	0.84
TTNP Titan Pharmaceuticals	N/A	11.60	11.60

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BRNS Barinthus Biotherapeutics	25.20%
QNCX Quince Therapeutics	30.75%
SGMO Sangamo Therapeutics	56.92%
TTNP Titan Pharmaceuticals	31.49%

Insider Ownership

Company	Insider Ownership
BRNS Barinthus Biotherapeutics	8.50%
QNCX Quince Therapeutics	5.60%
SGMO Sangamo Therapeutics	4.10%
TTNP Titan Pharmaceuticals	0.72%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BRNS Barinthus Biotherapeutics	107	40.85 million	37.38 million	N/A
QNCX Quince Therapeutics	60	1.02 million	960,000	Optionable
SGMO Sangamo Therapeutics	480	414.29 million	397.29 million	Optionable
TTNP Titan Pharmaceuticals	10	1.33 million	1.32 million	Optionable

TTNP, QNCX, SGMO, and BRNS Headlines

Recent News About These Companies

Titan Pharmaceuticals, Inc. Announces Closing of Merger with Black Titan Corporation

October 3, 2025 | globenewswire.com

Titan Pharmaceuticals Approves Merger with Black Titan

August 26, 2025 | msn.com

TITAN PHARMACEUTICALS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Merger of Titan Pharmaceuticals, Inc. - TTNP

August 5, 2025 | businesswire.com

URGENT: The M&A Class Action Firm Encourages $hareholders to Act Before Vote – Titan Pharmaceuticals, Inc. (Nasdaq: TTNP)

July 29, 2025 | globenewswire.com

Titan Pharmaceuticals Inc (TTNP) - Investing.com

July 4, 2025 | investing.com

Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock - Morningstar

June 29, 2025 | morningstar.comM

Titan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management - Nasdaq

June 29, 2025 | nasdaq.com

Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock

June 27, 2025 | finance.yahoo.com

Titan Pharmaceuticals Completes Private Placement of Series C Convertible Preferred Stock with Blue Harbour Asset Management

June 27, 2025 | quiverquant.comQ

Titan Pharmaceuticals Announces $600,000 Private Placement of Convertible Preferred Stock

June 27, 2025 | globenewswire.com

titan pharmaceuticals issues common stock following preferred stock conversions

June 4, 2025 | investing.com

Titan announces filing of registration statement for proposed combination

June 4, 2025 | finance.yahoo.com

Titan Pharmaceuticals, Inc. Files Registration Statement for Proposed Merger with TalenTec Sdn. Bhd.

June 3, 2025 | quiverquant.comQ

Titan Pharmaceuticals Announces Filing of Registration Statement for Proposed Business Combination with TalenTec Sdn. Bhd.

June 3, 2025 | globenewswire.com

Titan Pharmaceuticals Announces $1 Million Private Placement of Convertible Preferred Stock

April 11, 2025 | globenewswire.com

Titan Pharmaceuticals: Q4 Earnings Snapshot

March 20, 2025 | sfgate.com

Titan Pharmaceuticals receives Nasdaq notice of non-compliance

November 27, 2024 | markets.businessinsider.com

Titan Pharmaceuticals Faces Nasdaq Compliance Challenges with Reporting and Audit Committee Requirements

November 27, 2024 | quiverquant.comQ

Titan Pharmaceuticals, Inc. Announces Receipt of Notice from Nasdaq

November 27, 2024 | globenewswire.com

Sanofi Eyes Breakout After Pharma Titan Rides Vaccine Sales To Quarterly Beat

October 25, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTNP, QNCX, SGMO, and BRNS Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

$0.74 0.00 (0.00%)

As of 09/11/2026

Barinthus Biotherapeutics plc, a clinical-stage biopharmaceutical company, engages in development of novel T cell immunotherapeutic candidates designed to guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company's development pipeline includes VTP-300, an immunotherapeutic candidate under phase 2 studies as a potential component of a functional cure for chronic hepatitis B virus (HBV) infection; VTP-200, a non-surgical product candidate under phase 2 studies for treating persistent high-risk human papillomavirus (HPV) infection; VTP-1000, an autoimmune preclinical candidate designed to treat patients with celiac disease; VTP-1100 product candidate to target HPV16+ cancers; and VTP-850/850, a second-generation immunotherapeutic candidate under phase 2 studies to treat recurrent prostate cancer. It is also involved in the development of partnered candidates, such as AB-729-202, which is under phase 2a studies for the treatment of patients with chronic HBV infection; VTP-600, an immunotherapy candidate under phase 1 studies as a potential treatment for NSCLC in combination with standard of care treatment, chemotherapy, and pembrolizumab; VTP-500, a prophylactic vaccine product candidate under phase 1 studies to prevent infection and subsequent disease caused by the MERS coronavirus; and VTP-400, a prophylactic vaccine candidate under phase 1 studies to prevent shingles in adults aged 50 years and older. In addition, the company offers Vaxzevria (formerly VTP-900 and AZD1222), a prophylactic vaccine for the prevention of COVID-19 Infection. Further, it has license, research and development, and collaboration agreements with OUI, NIH, IMC, CanSino, CRUK; VOLT; and Arbutus. The company was formerly known as Vaccitech plc and changed its name to Barinthus Biotherapeutics plc in November 2023. Barinthus Biotherapeutics plc was founded in 2016 and is headquartered in Didcot, the United Kingdom.

Quince Therapeutics NASDAQ:QNCX

$29.55 +0.59 (+2.04%)

Closing price 09/11/2026 04:00 PM Eastern

Extended Trading

$29.50 -0.05 (-0.15%)

As of 09/11/2026 07:30 PM Eastern

Quince Therapeutics, Inc., a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene. Its AIDE technology platform, a drug/device combination platform that uses an automated process to encapsulate a drug into a patient's own red blood cells, as well as consists of an automated equipment the RCL, a sterile single-use consumable treatment kit comprising EryKit, Syringe Kit, drugs, and process solutions. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.

Sangamo Therapeutics NASDAQ:SGMO

$0.07 0.00 (0.00%)

As of 09/11/2026

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease. Its preclinical development products focus on CAR-Treg cell therapies for autoimmune disorders and genome engineering for neurological diseases. Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; Open Monoclonal Technology, Inc.; and California Institute for Regenerative Medicine. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. Sangamo Therapeutics, Inc. was incorporated in 1995 and is headquartered in Richmond, California.

Titan Pharmaceuticals NASDAQ:TTNP

Titan Pharmaceuticals, Inc., a pharmaceutical company, develops therapeutics for the treatment of chronic diseases in the United States and internationally. It develops products based on ProNeura, a proprietary long-term drug delivery platform. It also develops TP-2021 in combination with ProNeura technology for the treatment of chronic pruritus, a severe and debilitating condition defined as itching of the skin lasting longer than six weeks; and Nalmefene implant program for the prevention of opioid relapse following detoxification of patients suffering opioid use disorder. The company was founded in 1991 and is based in South San Francisco, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TTNP, QNCX, SGMO, and BRNS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TTNP, QNCX, SGMO, and BRNS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TTNP, QNCX, SGMO, and BRNS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTNP, QNCX, SGMO, and BRNS Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

Quince Therapeutics NASDAQ:QNCX

Sangamo Therapeutics NASDAQ:SGMO

Titan Pharmaceuticals NASDAQ:TTNP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest TTNP, QNCX, SGMO, and BRNS Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest TTNP, QNCX, SGMO, and BRNS Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

TTNP, QNCX, SGMO, and BRNS Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

TTNP, QNCX, SGMO, and BRNS Company Descriptions

Barinthus Biotherapeutics NASDAQ:BRNS

Quince Therapeutics NASDAQ:QNCX

Sangamo Therapeutics NASDAQ:SGMO

Titan Pharmaceuticals NASDAQ:TTNP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools